Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02751359
Recruitment Status : Completed
First Posted : April 26, 2016
Results First Posted : May 12, 2021
Last Update Posted : May 12, 2021
Sponsor:
Collaborator:
INSYS Therapeutics Inc
Information provided by (Responsible Party):
Ziva D. Cooper, PhD, University of California, Los Angeles

Brief Summary:
The purpose of this double-blind, placebo-controlled study is to determine the analgesic effects of cannabidiol (CBD), a chemical constituent found in cannabis that does not have intoxicating effects. The analgesic effects of CBD will be assessed using the Cold-Pressor Test (CPT), a laboratory model of pain which has predictive validity for the clinical use of analgesics.

Condition or disease Intervention/treatment Phase
Pain Drug: Cannabidiol Drug: Placebo Phase 1 Phase 2

Detailed Description:
This within-subject, double-blind, placebo-controlled study will assess the analgesic and subjective effects of a range of CBD doses (0, 200, 400, or 800 mg, po). Volunteers will participate in 4 outpatient laboratory sessions over the course of 4 weeks during which the analgesic effects of CBD will be assessed using the Cold-Pressor Test (CPT), a laboratory model of pain which has predictive validity for the clinical use of analgesics. The order of CBD dose will be randomized across participants. Secondary measures will include subjective and physiologic effects of CBD.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Characterization of the Analgesic Effects of Oral CBD in Healthy, Normal Volunteers
Actual Study Start Date : July 2016
Actual Primary Completion Date : July 2017
Actual Study Completion Date : April 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Cannabidiol

Arm Intervention/treatment
Active Comparator: Active CBD
Each subject will receive each active dose of cannabidiol, one active dose per 3 of the 4 study days. The active cannabidiol doses include 200, 400 and 800 mg of cannabidiol.
Drug: Cannabidiol
200, 400, or 800 mg Cannabidiol
Other Name: CBD

Placebo Comparator: Placebo
On 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg)
Drug: Placebo
0 mg Cannabidiol




Primary Outcome Measures :
  1. Analgesia: Change From Baseline in Pain Tolerance and Threshold as Measured by the Cold Pressor Test [ Time Frame: Baseline, 60 minutes, 120 minutes 180 minutes, 240 minutes, 300 minutes and 360 minutes after each dose ]
    Time to first feel pain ("Pain threshold" measured in seconds) during the Cold Pressor Test and withdraw the hand from the cold water ("Pain Tolerance" measured in seconds). Changes in threshold from baseline were averaged across study sessions for each CBD dose.


Secondary Outcome Measures :
  1. Subjective Drug Effects Related to Abuse Liability as Measured by Visual Analog Scales [ Time Frame: 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 210 minutes, 270 minutes, 300 minutes, 330 minutes, 360 minutes ]
    Participants rate the strength of their desire to take again, drug liking, good effect and bad effect. Each item was presented and the participant was asked to rate his / her rating on a scale anchored by 'Not At All' (0 mm) to 'Extremely' (100 mm). The average of all timepoints is reported for each category.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Able to perform study procedures
  • Women practicing an effective form of birth control

Exclusion Criteria:

  • Female subjects who are currently pregnant or breastfeeding.
  • Current illicit drug use
  • Presence of significant medical illness
  • History of heart disease
  • Request for drug treatment
  • Current parole or probation
  • Recent history of significant violent behavior
  • Major psychiatric disorder
  • Current use of any prescription or over-the-counter medication
  • Current pain
  • Clinically significant Raynaud's syndrome

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02751359


Locations
Layout table for location information
United States, New York
Cooper
New York, New York, United States, 10013
Sponsors and Collaborators
University of California, Los Angeles
INSYS Therapeutics Inc
Investigators
Layout table for investigator information
Principal Investigator: Ziva D Cooper, PhD New York State Psychiatric Institute / CUMC
  Study Documents (Full-Text)

Documents provided by Ziva D. Cooper, PhD, University of California, Los Angeles:
Layout table for additonal information
Responsible Party: Ziva D. Cooper, PhD, Associate Professor of Clinical Neurobiology (in Psychiatry), University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT02751359    
Other Study ID Numbers: 7009
First Posted: April 26, 2016    Key Record Dates
Results First Posted: May 12, 2021
Last Update Posted: May 12, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cannabidiol
Anticonvulsants